Replimune Group, Inc.

NasdaqGS:REPL Stock Report

Market Cap: US$960.3m

Replimune Group Future Growth

Future criteria checks 2/6

Replimune Group is forecast to grow earnings and revenue by 37% and 47.8% per annum respectively while EPS is expected to grow by 40.8% per annum.

Key information

37.0%

Earnings growth rate

40.78%

EPS growth rate

Biotechs earnings growth25.3%
Revenue growth rate47.8%
Future return on equityn/a
Analyst coverage

Good

Last updated26 Jun 2026

Recent future growth updates

Recent updates

Seeking Alpha • Jun 05

Replimune: Modeling The Coin Flip Of FDA Approval

Summary Replimune remains a high-risk, high-reward play ahead of a third FDA decision on RP1 in advanced melanoma. Current valuation implies a 50% near-term probability of RP1 approval, but risk-reward is not compelling given binary near-term catalysts. RP1 approval could push REPL to $14.99/share, while a third CRL may drive shares toward cash value near $3 with heavy dilution risk. I maintain a 'Hold' rating on REPL, citing limited market opportunity, unpredictable FDA dynamics, and the need for cautious position sizing. Read the full article on Seeking Alpha
Analysis Article • Feb 08

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Aug 01

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Apr 28

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Summary Replimune Group, Inc.'s BLA of RP1 + OPDIVO in advanced melanoma received an FDA Priority Review, with a PDUFA date set for July 22, 2025. RP2, adding an anti-CTLA-4 component, is being tested in metastatic uveal melanoma and 2nd-line metastatic hepatocellular carcinoma patients. Financially, Replimune has $536.5 million in cash, but REPL will likely need additional funding within the next 12 months. The global liver cancer drugs market is expected to reach $14.9 billion by 2031. Read the full article on Seeking Alpha
Analysis Article • Apr 11

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Feb 12

Replimune: A Misunderstood Contender In Oncolytics

Summary Replimune Group's solid cash position and strategic focus on niche oncology markets position it for potential success, despite market volatility and past trial setbacks. The company's RP1 and RP2 platforms target unmet needs in melanoma and other cancers, with promising data and regulatory momentum supporting their potential. The FDA's Priority Review and Breakthrough Therapy designations for RP1 underscore its potential to reshape second-line melanoma treatment and expedite market entry. Despite skepticism about oncolytic viruses, Replimune's approach and collaborations with big pharma could yield significant commercial opportunities if clinical data remains strong. Read the full article on Seeking Alpha
Seeking Alpha • Nov 29

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Summary Replimune has submitted its BLA of RP1 + Opdivo for the treatment of advanced melanoma patients previously treated with an anti-PD1 containing regimen. The phase 3 confirmatory IGNYTE-3 study is underway to prove yet again that RP1 + Opdivo is able to help these patients with advanced melanoma and to keep the drug marketed. The global melanoma therapeutics market size is projected to reach $17.93 billion by 2034. RP2 is another drug in the company's pipeline which is being developed other than target metastatic uveal melanoma and Hepatocellular Carcinoma patients. Read the full article on Seeking Alpha
Analysis Article • Nov 23

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Sep 03

Replimune: Strong Data In A Highly Differentiated Space

Summary Replimune's RP1, an oncolytic immuno-gene therapy, shows promise with a 31.4% ORR in phase 2 trials for post PD-1 melanoma and non-melanoma skin cancers. RP2, adding an anti-CTLA-4 component to RP1, demonstrated a 29.4% ORR in phase 1 trials, with durable responses in difficult-to-treat tumors. Despite competitive challenges and a failed CSCC trial, Replimune's cash runway supports its accelerated approval and phase 3 trials, making it an attractive investment. RP1 and RP2 together could be a game-changer, offering a compelling opportunity at current low stock prices. Read the full article on Seeking Alpha
Analysis Article • Aug 16

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • May 22

Replimune: Continuing To Justify The Bear Thesis (For Now)

Summary Replimune Group, Inc.'s stock has fallen 35% in 2024, and an inflection point is not expected yet. The company is working on RP1, an oncolytic virus therapy, and has shared positive results from their ARTACUS trial. Replimune plans to submit a BLA for RP1 approval in melanoma, but this is far from guaranteed, especially in 2024. Read the full article on Seeking Alpha
Analysis Article • Feb 06

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Jan 23

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Summary Replimune Group is developing virus-based treatments for solid tumors, particularly skin cancer. The company's RP1 treatment did not show significant improvement in response rates compared to standard care in a phase 1/2 study, though there is a signal of something buried therein. Replimune plans to initiate a confirmatory study for RP1 in melanoma patients and is also developing RP2 for uveal melanoma. Read the full article on Seeking Alpha
Analysis Article • Dec 25

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Key Insights The projected fair value for Replimune Group is US$9.64 based on 2 Stage Free Cash Flow to Equity Current...
Analysis Article • Jul 13

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Apr 05

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Jan 06

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Key Insights Replimune Group's estimated fair value is US$25.6 based on 2 Stage Free Cash Flow to Equity Current share...

Earnings and Revenue Growth Forecasts

NasdaqGS:REPL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2029103-87-36-34
3/31/202861-145-105-925
3/31/20278-216-176-1858
3/31/20264-310-116-2608
12/31/2025N/A-315-283-278N/A
9/30/2025N/A-310-270-263N/A
6/30/2025N/A-280-228-220N/A
3/31/2025N/A-247-199-192N/A
12/31/2024N/A-228-192-185N/A
9/30/2024N/A-213-188-181N/A
6/30/2024N/A-220-193-186N/A
3/31/2024N/A-216-191-185N/A
12/31/2023N/A-210-176-172N/A
9/30/2023N/A-199-157-154N/A
6/30/2023N/A-182-145-143N/A
3/31/2023N/A-174-130-128N/A
12/31/2022N/A-157-121-118N/A
9/30/2022N/A-147-111-108N/A
6/30/2022N/A-133-100-97N/A
3/31/2022N/A-118-85-82N/A
12/31/2021N/A-108-78-76N/A
9/30/2021N/A-100-72-70N/A
6/30/2021N/A-91-66-65N/A
3/31/2021N/A-81-64-61N/A
12/31/2020N/A-75-59-57N/A
9/30/2020N/A-70-66-59N/A
6/30/2020N/A-61-69-62N/A
3/31/2020N/A-53-67-61N/A
12/31/2019N/A-43-62-55N/A
9/30/2019N/A-35N/A-46N/A
6/30/2019N/A-30N/A-32N/A
3/31/2019N/A-31N/A-25N/A
12/31/2018N/A-31N/A-24N/A
9/30/2018N/A-28N/A-20N/A
6/30/2018N/A-26N/A-17N/A
3/31/2018N/A-20N/A-16N/A
12/31/2017N/A-17N/A-15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: REPL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: REPL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: REPL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: REPL's revenue (47.8% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: REPL's revenue (47.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if REPL's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/28 02:56
End of Day Share Price 2026/06/26 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Replimune Group, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Clarence PowellBMO Capital Markets Equity Research
Evan SeigermanBMO Capital Markets Equity Research
Guyn KimBMO Capital Markets Equity Research